Schering divests its stake in Medac

Published: 1-Aug-2005


Schering has sold its 25% stake in Medac to the company's shareholders for a 'two-digit million Euro figure'.

The move coincides with Schering's acquisition of the remaining 50% of shares in the joint venture Medac Schering Onkologie, the activities of which are to be integrated into a new oncology business unit at Schering's German subsidiary, Schering Deutschland.

It focuses on the marketing of products for the treatment of haematological malignancies in Germany.

You may also like